EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 12th, 2020 • X4 Pharmaceuticals, Inc • Biological products, (no disgnostic substances) • Massachusetts
THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of September 25, 2019, (the “Effective Date”) by and between X4 Pharmaceuticals, Inc. (the “Company”), and Derek M. Meisner (“Executive”) (collectively referred to as the “Parties” or individually referred to as a “Party”).
ContractX4 Pharmaceuticals, Inc • March 12th, 2020 • Biological products, (no disgnostic substances) • Massachusetts
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 12th, 2020 • X4 Pharmaceuticals, Inc • Biological products, (no disgnostic substances) • Massachusetts
This Executive Employment Agreement (the “Agreement”), is made and entered into this 22nd day of April, 2019 (the “Effective Date”), and is by and between X4 Pharmaceuticals, Inc. (“Company”), and E. Lynne Kelley, M.D. (“Executive”).
AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 12th, 2020 • X4 Pharmaceuticals, Inc • Biological products, (no disgnostic substances)
This amendment (this “Amendment”) to that certain Executive Employment Agreement, dated April 22, 2019 (the “Employment Agreement”), as amended by the Severance Plan Addendum to Executive Employment Agreement adopted by the Board of Directors on September 18, 2019 (the “Plan Addendum”) (collectively, the “Kelley Agreement”) by and between E. Lynne Kelley, MD, FACS (“Employee”) and X4 Pharmaceuticals, Inc. (the “Company”) is entered into as of this 5th day of March, 2020.
MASTER SERVICES AGREEMENTMaster Services Agreement • March 12th, 2020 • X4 Pharmaceuticals, Inc • Biological products, (no disgnostic substances) • New York
This Master Services Agreement (this “Agreement”) is made effective as of February 19, 2016 (the “Effective Date”), by and between X4 Pharmaceuticals, Inc., a Delaware corporation with a business address at 784 Memorial Drive, Suite 140, Cambridge, MA 02139 (“X4”), and Aptuit (Oxford) Limited incorporated in England and Wales, having an address at 111 Innovation Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RZ, England (the “Company”). X4 and the Company are each sometimes hereinafter referred to individually as a “Party” and collectively as the “Parties.”
AMENDMENT No. 1 TO THE MASTER SERVICES AGREEMENT RECITALSThe Master Services Agreement Recitals • March 12th, 2020 • X4 Pharmaceuticals, Inc • Biological products, (no disgnostic substances)
This Amendment No. 1 (the “Amendment”) is made as of August 25th, 2017 (“Effective Date”) by and between Mayne Pharma Inc. (formerly known as Metrics, Inc.), doing business as Metrics Contract Services, a North Carolina corporation, having a principal place of business at 1240 Sugg Parkway, Greenville, NC 27834 (“Metrics”) and X4 Pharmaceuticals Inc., a Delaware corporation with a business address at 955 Massachusetts Avenue, Fourth Floor, Cambridge, MA 02139 (“Company”).
AMENDMENT NO. 1 TO MASTER SERVICES AGREEMENTMaster Services Agreement • March 12th, 2020 • X4 Pharmaceuticals, Inc • Biological products, (no disgnostic substances)
This amendment (the "Amendment") to the Master Services Agreement by and between X4 Pharmaceuticals, Inc., a Delaware corporation with a business address at 784 Memorial Drive, Suite 140, Cambridge, MA 02139 ("X4"), and Aptuit (Oxford) Limited, incorporated in England and Wales, having an address at 111 Innovation Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RZ, England (the "Company"), dated February 19, 2016 (the "Agreement"), incorporated by reference herein, is effective on 23rd November 2016 (the "Effective Date").
MASTER SERVICES AGREEMENTMaster Services Agreement • March 12th, 2020 • X4 Pharmaceuticals, Inc • Biological products, (no disgnostic substances) • Delaware
day of September, 2015 (the "Effective Date"), by and between Metrics, Inc., doing business as Metrics Contract Services, a North Carolina corporation, having a principal place of business at 1240 Sugg Parkway, Greenville, NC 27834 ("METRICS"), and X4 Pharmaceuticals, Inc., a Delaware corporation having an address at Cambridge Innovation Center, One Broadway, Cambridge, MA 02142 ("COMPANY").
AMENDMENT TO MEISNER EMPLOYMENT AGREEMENTSMeisner Employment Agreements • March 12th, 2020 • X4 Pharmaceuticals, Inc • Biological products, (no disgnostic substances)
This amendment (this “Amendment”) to that certain Executive Employment Agreement, dated September 25, 2019 (the “Employment Agreement”) by and between Derek M. Meisner (“Employee”) and X4 Pharmaceuticals, Inc. (the “Company”), and the Confidentiality, Non-Solicitation, Intellectual Property and Change of Control Agreement (the “CNIPCA), dated September 29, 2019, by and between Employee and the Company, is entered into as of this 24th day of February, 2020.
AMENDMENT TO AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 12th, 2020 • X4 Pharmaceuticals, Inc • Biological products, (no disgnostic substances)
This amendment (this “Amendment”) to that certain Amended and Restated Executive Employment Agreement, dated March 13, 2019 (the “Employment Agreement”), as amended by the Severance Plan Addendum to Executive Employment Agreement adopted by the Board of Directors on September 18, 2019 (the “Plan Addendum”) (collectively, the “Mostafa Agreement”) by and between Adam S. Mostafa, MD, FACS (“Employee”) and X4 Pharmaceuticals, Inc. (the “Company”) is entered into as of this 24th day of February, 2020.
AMENDMENT TO AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 12th, 2020 • X4 Pharmaceuticals, Inc • Biological products, (no disgnostic substances)
This amendment (this “Amendment”) to that certain Amended and Restated Executive Employment Agreement, dated March 13, 2019, (the “Agreement”) by and between Paula Ragan, Ph.D (“Employee”) and X4 Pharmaceuticals, Inc. (the “Company”) is entered into as of this 13th day of February, 2020.
AMENDMENT No. 2 TO THE MASTER SERVICES AGREEMENTThe Master Services Agreement • March 12th, 2020 • X4 Pharmaceuticals, Inc • Biological products, (no disgnostic substances)
This Amendment No. 2 (the “Amendment”) is made as of February 28th, 2020 (“Effective Date”) by and between Mayne Pharma Inc. (formerly known as Metrics, Inc.), doing business as Metrics Contract Services, a North Carolina corporation, having a principal place of business at 1240 Sugg Parkway, Greenville, NC 27834 (“Metrics”) and X4 Pharmaceuticals Inc., a Delaware corporation with a business address at 955 Massachusetts Avenue, Fourth Floor, Cambridge, MA 02139 (“Company”).
